Navigation Links
NCE in Medical News

C3Life.com to Sponsor Fashion Show at 2009 National UOAA Conference

Ostomy event to showcase clothing, lingerie, and fashion tips for people with ostomies Libertyville, IL USA (PRWEB) July 29, 2009 -- C3Life.com , a community website for people with ostomies, their caregivers, and loved ones, will be sponsoring a fashion show at the Se...

Minnesotans to Keynote Materials for Medical Devices Conference

Two leading Minnesota-based innovators in the field of medical implants will keynote the upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton Minneapolis. (Vocus) July 27, 2009 -- Two leading Minnesota-based innovators in the field...

Reed Group Will Debut New Predictive Modeling Tool at DMEC Conference

Companies whose disability case managers rely only on standard return-to-work durations may be throwing away millions of dollars, says Reed Group President, Guidelines, Jon Seymour, MD. Westminster, CO (Vocus) July 16, 2009 -- Companies whose disability case managers re...

Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance

As the health care reform details emerge, more entrepreneurs are wondering about health insurance for small groups and business insurance premiums. Now, they are getting some answers and are turning to websites such as the Small Business Health Insurance Network to find coverage. ...

Interest in the Bariatric Advantage Chewy Bites and Other New Products is at an All-Time High at the ASMBS Conference

Bariatric Advantage, a Division of Catalina Lifesciences, could barely keep up with demand to sample and learn about their new products at the ASMBS conference. The Company located in Booth #1011 had 20-30 healthcare professionals throughout the entire day. Dallas, TX ...

Understand ARRA Spending Allocations with HIMSS Analytics™ Market Intelligence

Essentials of the US Hospital IT Market - 4th Edition provides a current overview and future projections of the US hospital information technology market Chicago, IL (Vocus) June 2, 2009 -- With more than $19 billion available for US hospitals and ambulatory clinics to ...

kidneySPA Introduces A Revolutionary Approach To Dialysis Treatment Newly Opened Facility Combines "Medical" Expertise with "Spa-Like" Experience

The highly-anticipated kidneySPA is finally open - its mission, to provide patients with a revolutionary dialysis experience by combining state-of-the-art medical treatment in a harmonious, spa-like setting. Located in Miami, Florida's Health District, this one-of-a-kind dialysis center serves pa...

Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference

Corepoint Health's CTO, Dave Shaver, will be an invited panelist in the second annual SOA in Healthcare conference to be held on June 2 - 4 in Chicago, Illinois. Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health's CTO, Dave Shaver, will be an invited panelist in the ...

Alice Stollenwerk Petrulis, MD, FACP, to Speak at 15th Annual MEDecision User Conference

Alice Stollenwerk Petrulis, MD, FACP, Chief Medical Officer for the Keystone Peer Review Organizations, Inc. (KePRO), an integrated care management and quality improvement organization, will be a featured speaker at the 15th Annual MEDecision User Conference to be held in Philadelphia May 6-8, 20...

Inteck, Inc. has been Selected to Conduct Two Presentations at the 2009 International MUSE Conference

Inteck, Inc. has been selected to conduct two educational presentations at 2009 International MUSE in Vancouver, BC Canada, May 26 -29. Inteck will also be an exhibitor and will offer participants additional opportunities to learn more about their seminars and to discuss other issues and quest...

More>>

NCE in Medical Technology

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

... naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented nce pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naprox...es for partnering. About LT-NS001 LT-NS001 is a novel, patented nce pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naprox...

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

...ory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

...ory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs...

ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

...there is an urgent need for this type of antibiotic. "The development of an nce for combination antibiotic treatment could be extremely beneficial," commen...ation antibiotic efficacy for the treatment of foreign body infections, the nce ABI-0043 was as effective as rifampin. The fact that ABI-0043 is not predic...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

... Mumbai, India. The Company is a leader in India in the discovery of new molecules. Glenmark has 11 lead molecules at various stages of development in nce & NBE research. Three of the leads are in Phase 2 whereas eight other leads are into the pre-clinical and discovery stages in the broad areas of infla...

Lilly and Glenmark Pharmaceuticals Announce License Agreement

... Mumbai, India. The Company is a leader in India in the discovery of new molecules. Glenmark has 11 lead molecules at various stages of development in nce & NBE research. Three of the leads are in Phase II whereas eight other leads are into the pre-clinical and discovery stages in the broad areas of infl...

More>>

NCE in Biological Technology

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

...tory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) anti-inflammatory agent for the treatment of the signs and symptoms of osteoarth...

NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

...ory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs...

Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward

...OACH TO IMI PLANNED Under the terms of the agreement, Oslo Cancer Cluster nce with Cancer-Bio-Sante Cluster and Toulouse Canceropole commit to cooperate ...ion in Atlanta. More information: Bjarte Reve, CEO, Oslo Cancer Cluster nce - cellphone: +47-971-09-585. Jean-Pierre Saintouil, CEO, Toulouse Cancer-...

SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)

...ndent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced nce is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30...

New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)

...ion of new kinase inhibitors." Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to nce discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners." About IOTA IOTA Pharmaceuticals provid...

ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials

...efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This nce (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year. The objectives of Allergan and ExonHit's stra...

Midwest Investment Bank Piper Jaffray Resurges in New York City

... 505(b)(2) pathway receive Waxman-Hatch market exclusivity (equivalent to patent protection) for three years for new labeling, up to five years for an nce and seven years under orphan drug designation. While this is not of great interest to Big Pharma because market exclusivity is too short, it is of gre...

More>>

Other Tags
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
Other Contents